ATHE
Alterity Therapeutics Ltd
$5.58
+0.09 (+1.64%)
At close · Jul 8
Market Cap
$101.14M
Shares
18,125,694
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.58
Open$5.62
Day$5.33–5.70
52W$2.66–7.00
Avg vol 30d78K
Short int54K · 0.3% float · 1.0d
Short vol32%
Last earningsDec 31, 2020
DataJan 2020–Jul 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+43%
above
Price vs 50-day avg
+22%
above
RSI (14)
64
neutral
MACD trend
Positive
52-week position
67%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+42%
trailing
6-month return
+64%
trailing
YTD return
+81%
this year
Relative strength
+57%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
2 of 15 funds reported for Jun 30 · net +453 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.30% of float · ▲ +486.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — mid 3-yr range
Squeeze score
27
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+43%
Bullish
Price vs 50-day avg
+22%
Bullish
RSI (14)
64
Neutral
MACD trend
Positive
Bullish
52-week position
67%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
2 of 15 funds reported for Jun 30 · net +453 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.30% of float · ▲ +486.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $3
Now $6 · 67%
52-wk high $7
vs 200-day avg +43%
vs 50-day avg +22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATHE
this stock
Alterity Therapeutics Ltd
|
$101.14M | +81.2% | — | — | 0.3% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATHE | +3.9% | +42.4% | +64.1% | +3.9% | +81.2% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +4.1% | +41.5% | +56.7% | +4.1% | +71.9% |